Business Context and Reporting Period
Nexalin Technology, Inc. (NXL) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The Company designs and develops non-invasive neurostimulation medical devices (Gen-1, Gen-2, and Gen-3) to treat anxiety, insomnia, depression, and other mental health conditions without drugs or psychotherapy.
Key operational context includes:
- Regulatory Status: The Gen-1 device (4mA) is FDA-cleared for anxiety and insomnia (Class II) but requires a new 510(k) application; depression treatment requires a Class III Premarket Approval (PMA). The Gen-2 device (15mA) is approved in China, Brazil, and Oman. The Gen-3 headset is in the FDA pre-submission process.
- Joint Venture: Nexalin holds a 48% interest in a Hong Kong-based Joint Venture with Wider Come Limited (52%) to market Gen-2 devices in China and the region.
- Capital Structure: The Company completed a follow-on public offering in July 2024, raising approximately $5.25 million gross proceeds.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $168,721 | $110,748 |
| Gross Profit | $132,128 | $85,060 |
| Gross Margin | 78.3% | 76.8% |
| Net Loss | $(7,607,182) | $(4,648,709) |
| Comprehensive Loss | $(7,607,290) | $(4,685,427) |
| Operating Cash Flow | $(3,944,390) | $(3,835,384) |
| Cash & Short-Term Investments (Dec 31, 2024) | $3,479,923 | $2,948,433 |
| Accumulated Deficit | $(84,645,231) | $(77,038,049) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 52% to $168,721, driven primarily by sales of supplies, parts, and increased China sales ($85,248 in 2024 vs. $3,614 in 2023).
- Operating Expenses: Total operating expenses rose 36% to $7.89 million. This was largely due to a 123% increase in Selling, General, and Administrative (SG&A) expenses, driven by a $2.25 million increase in stock-based compensation and higher professional fees. Research and Development (R&D) expenses decreased 38% to $1.19 million due to fewer clinical trial costs incurred in 2024.
- Net Loss Expansion: Net loss increased 64% to $7.61 million, reflecting higher operating costs and a decrease in "Other Income" (specifically the absence of a $615,000 gain on debt extinguishment recorded in 2023).
- Equity Issuance: The Company issued 3 million shares in July 2024, increasing cash reserves and stockholders' equity.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance: Management does not provide specific financial guidance. The Company anticipates continuing to incur operating losses through 2025 as it executes development plans for Gen-3 and seeks FDA approvals. Management has concluded that existing cash and short-term investments will not be sufficient to satisfy anticipated cash requirements for the next twelve months.
Going Concern: The independent auditor has issued an opinion with an explanatory paragraph regarding "Going Concern," stating there is substantial doubt about the Company's ability to continue as a going concern without additional financing.
Key Risks:
- Regulatory Uncertainty: Success depends on FDA clearance for Gen-3 and PMA for depression treatment. The Gen-1 device marketing is paused in the U.S. pending new applications.
- China Operations: Risks related to the Joint Venture include Chinese regulatory changes, data privacy laws, and enforcement of intellectual property rights.
- Internal Controls: The Company identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and IT user access controls.
- Liquidity: The Company relies on equity offerings to fund operations. Failure to raise capital could force delays in clinical trials or commercialization.
Legal Contingencies:
- Sarah Veltz v. Nexalin: Pending lawsuit alleging unpaid wages and sexual harassment. Trial set for June 9, 2025. No loss estimate can be provided.
- Employment Development Department (EDD): Settlement discussions regarding worker classification. Accrued liability is $40,000.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "Going Concern" warning and management's statement that current funds are insufficient for 12 months.
- FDA Pre-Submission Status: Confirm the specific feedback received from the FDA regarding the Gen-3 HALO headset and the timeline for the planned clinical trials in Q1 2025.
- China Revenue Sustainability: Assess the reliance on the Joint Venture for revenue growth and the risks associated with Chinese regulatory enforcement and data laws.
- Internal Control Remediation: Review the Company's plan and budget to remediate the identified material weaknesses in financial reporting controls.
- Related Party Transactions: Scrutinize the terms of the Joint Venture with Wider Come Limited and the consulting agreement with U.S. Asian Consulting Group (controlled by the Controller's spouse).